Pillar Biosciences Secures $1,352 Medicare Reimbursement Rate for oncoReveal CDx Ahead of IPO

Dec 09, 2025 14:00 CST Updated 14:00

Illumina

Diagnostic Product Developer

Source: Following the Cause and Investigating Medicine

On December 1, 2025, Pillar Biosciences (ZhenGu Biotech) received the final decision from the Centers for Medicare & Medicaid Services (CMS).The companion diagnostic product, oncoReveal CDx, is priced at $1,352.09., to be implemented starting January 1, 2026.

This product contains 22 genes, among which the EGFR and KRAS genes correspond to companion diagnostics for multiple tumor treatment targeted drugs.

oncoReveal CDx uses a multiplex PCR library sequencing method, based on the Illumina MiSeq Dx platform, and its PMA application was approved by the FDA on July 30, 2021.

2023Year 7, Month 25On [date], Illumina, Inc. issued an announcement declaring its collaboration with Pillar.Biosciences Forms Partnership to Advance Personalized Cancer Treatment.

April 3, 2025oncoReveal CDxObtained CMS Medicare reimbursement approval.

On May 7, 2025, Pillar announced that it had received a strategic investment of $34.5 million, mainly from Illumina.

Everything is the best arrangement...

For the introduction of Pillar, welcome to review.

Illumina Partners with Pillar Biosciences to Tap into Oncology Market: Has Twist Bioscience Turned from Sweetheart to Outcast?

Anyway, $1352 seems to be about the same in China and the US without considering the exchange rate.

Emmm, without considering the exchange rate.

Statement: The articles published on this WeChat platform that are cited from other sources are reprinted, intended solely for sharing purposes, and do not represent the platform's position. If there are any copyright issues or other problems, please contact us as soon as possible, and we will make corrections immediately.